Biomarkers for susceptibility to infection and disease severity in human malaria

Bruno Bezerril Andrade¹, Manoel Barral-Netto², ³, ⁴/+

¹Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
²Faculdade de Medicina, Universidade Federal da Bahia, Salvador, BA, Brasil ³Centro de Pesquisas Goiçalo Moniz-Fiocruz, Salvador, BA, Brasil
⁴Instituto Nacional de Ciência e Tecnologia de Investigação em Imunologia, Salvador, BA, Brasil

Malaria remains a major infectious disease that affects millions of people. Once infected with Plasmodium parasites, a host can develop a broad range of clinical presentations, which result from complex interactions between factors derived from the host, the parasite and the environment. Intense research has focused on the identification of reliable predictors for exposure, susceptibility to infection and the development of severe complications during malaria. Although most promising markers are based on the current understanding of malaria immunopathogenesis, some are also focused more broadly on mechanisms of tissue damage and inflammation. Taken together, these markers can help optimise therapeutic strategies and reduce disease burden. Here, we review the recent advances in the identification of malarial biomarkers, focusing on those related to parasite exposure and disease susceptibility. We also discuss priorities for research in biomarkers for severe malaria.

Key words: malaria - Plasmodium - biomarker - inflammation

Despite continuous efforts by both governmental and private initiatives to eliminate malaria, Plasmodium infections still result in millions of deaths annually worldwide. Approximately two thirds of the world’s population lives in areas at risk for malaria (Guerra et al. 2008, Hay et al. 2009). Among the five Plasmodium species that can cause human disease, Plasmodium falciparum and Plasmodium vivax represent the majority of infections. In fact, globally, P. falciparum has been responsible for the majority of malaria-associated mortality (Guerra et al. 2008); however, vivax malaria, previously considered a benign disease, has now clearly emerged as a potentially lethal condition (Anstey et al. 2009), particularly in non-African endemic regions. P. vivax is also more widely distributed than P. falciparum and has potential to cause morbidity and mortality amongst the 2.85 billion people living at risk of infection (Guerra et al. 2010). In Brazil, P. vivax accounts for up to 80% of the malaria cases (Oliveira-Ferreira et al. 2010). Techniques for adequate malaria control are based on the development of sensitive diagnostic tools, effective treatments and the successful implementation of preventive strategies using bed nets and insecticides. Despite more than 40 years of tremendous investments, no reliable vaccine is available to prevent malaria, in part because Plasmodium parasites have evolved a number of evasion mechanisms that subvert host immune responses. Understanding the nuances of malaria immunopathogenesis is fundamental to the development of innovative approaches to reduce disease burden.

Once infected with Plasmodium, a human host generally presents with one of three major clinical outcomes: asymptomatic infection, mild disease or severe disease. These diverse clinical presentations are determined by complex interactions between the host, the parasite and environmental factors (Fig. 1). Parasite determinants include the different pathogenic potential of the various Plasmodium species. For example, P. falciparum is well known to cause severe infections more frequently than other Plasmodium species because P. falciparum exhibits a number of unique characteristics that favour increased disease severity, including high multiplication rates in both erythrocytes and reticulocytes, strong cytoadherence to infected erythrocytes [reviewed in Schofield (2007)] and toxin-induced activation of inflammatory responses [reviewed in Clark and Cowden (1999)]. Interestingly, cases of severe malaria caused by P. vivax (Andrade et al. 2010c) or uncommon Plasmodium species (Cox-Singh et al. 2010) display patterns of inflammation and immunopathology similar to those seen in severe falciparum malaria cases. These findings suggest that different Plasmodium species can trigger strikingly similar host responses that can result in severe disease. A number of host factors have already been described as important determinants of clinical outcomes in malaria cases, including age and gender, ethnicity, concomitant chronic conditions, co-infections and diverse genetic polymorphisms. Environmental factors include deforestation, health care system infrastructure and access to effective antimalarial treatment, vector exposure and sociocultural factors. Within the clinical spectrum of Plasmodium infections, we consider the two opposite poles that remain to be fully understood of utmost importance: asymptomatic malaria, which is directly associated with clinical immunity to infection and severe malaria, which underlies key processes in susceptibility to infection.
Severe and lethal disease. Furthermore, an infected individual can progress from one clinical presentation to another depending on additional factors such as therapeutic efficacy, parasite drug resistance, changes in parasite virulence and changes in host immunocompetence. A major challenge is to identify reliable predictors of undesirable outcomes and reduce disease burden. Rx: treatment.

Several epidemiological studies have shown that cases of asymptomatic malaria are highly prevalent in many endemic regions (Cucunubá et al. 2008, Baliraine et al. 2009, Marangi et al. 2009, Steenkeste et al. 2010). Individuals with asymptomatic Plasmodium infection can exhibit low parasitaemia for up to 60 days (Alves et al. 2002). Because of the absence of symptoms, these infected individuals do not seek health care at malaria reference centres. Furthermore, active detection of asymptomatic malaria cases is hampered by the low sensitivity of microscopy-based detection techniques in identifying very low parasite burdens (Andrade et al. 2010b). Moreover, despite low concentrations of circulating parasites, individuals with asymptomatic malaria infections can transmit Plasmodium to uninfected vectors (Alves et al. 2005). This phenomenon suggests that individuals with asymptomatic Plasmodium infections may serve as an important parasite reservoir in endemic areas.

Major factors associated with asymptomatic malaria are related to the magnitude of parasite and vector exposure (Bejon et al. 2009). Indeed, it is well established that the occurrence of asymptomatic malaria is associated with increased age (Baird et al. 1991), time of residence in the endemic area and number of previous malaria episodes (Rogier & Trape 1995). After many years of repeated infections, the host develops clinical immunity against Plasmodium. In these cases, the onset of symptoms is prevented by limiting parasite burden and controlling inflammation (Fig. 2). Intriguingly, such asymptomatic carriers have developed just enough immunity to protect them from malarial illness, but not from malarial infection. Thus, the search for biomarkers of clinical immunity must explore tools to estimate both parasite/vector exposure and the host’s own protective responses. Important general concepts related to biomarkers are presented in Fig. 3.

The hallmark symptom of malaria is fever, which can be followed by a wide range of other symptoms including headache, chills, diarrhea, lethargy, coughing fits and abdominal or muscular pain (Greenwood et al. 2005). Further, more severe manifestations of malaria also vary and include anaemia, hypoglycaemia, hypotension, intense haemolysis, metabolic acidosis, spontaneous bleeding, hepatitis, acute kidney failure, respiratory distress, convulsion, coma and multiple organ failure (WHO 2000). Notably, while the parameters defining severe malaria are standardised with regard to P. falciparum infections, there are as yet no consensus criteria measuring severity of vivax malaria infections. Although the hallmark symptom of malaria is fever, which can be followed by a wide range of other symptoms including headache, chills, diarrhea, lethargy, coughing fits and abdominal or muscular pain (Greenwood et al. 2005). Further, more severe manifestations of malaria also vary and include anaemia, hypoglycaemia, hypotension, intense haemolysis, metabolic acidosis, spontaneous bleeding, hepatitis, acute kidney failure, respiratory distress, convulsion, coma and multiple organ failure (WHO 2000). Notably, while the parameters defining severe malaria are standardised with regard to P. falciparum infections, there are as yet no consensus criteria measuring severity of vivax malaria infections. One simple approach that has been explored is based on outcomes of clinical and laboratory tests, which are used to predict overall mortality and specific complications (Mishra et al. 2007, Winkler et al. 2008). Unlike in cases of asymptomatic malaria, parasitological diagnosis is not a major concern in severe cases, as most patients present with high levels of parasitaemia that are easily detected by microscopy-based techniques. In these situations, the critical point is to exclude mixed Plasmodium infections and other comorbidities, such as bacterial sepsis, leptospirosis, dengue, viral hepatitis and acquired immune deficiency syndrome, that can result in similar clinical presentations. Thus, the search for highly specific mark-
Anopheles salivary gland sonicates (SGS), as described by Andrade et al. (2005), have been reviewed. Vermin anti-saliva immune response. Immediate, delayed and non-infective responses may be directly linked to changes in host immune responses. Depinay et al. (2006); furthermore, several of the active molecules present in vector saliva are immunogenic to vertebrate hosts, resulting in the initiation of the active molecules present in vector saliva are immunogenic to vertebrate hosts, resulting in the initiation of the active molecules present in vector saliva. Immediate, delayed and non-specific markers, such as those that indicate inflammatory status, are also extremely important in the identification of useful surrogate and specific biomarkers for cases of severe malaria.

**Biomarkers of exposure - Plasmodium** is transmitted through the bites of *Anopheles* mosquitoes. As the insect takes a blood meal, arthropod saliva is injected into the vertebrate host. Vector saliva is essential for the Plasmodium life cycle (Choumet et al. 2007), facilitating blood feeding by inhibiting host coagulation and inflammatory responses reviewed in Andrade et al. (2005). These effects may be directly linked to changes in host immune response (Depinay et al. 2006); furthermore, several of the active molecules present in vector saliva are immunogenic to vertebrate hosts, resulting in the initiation of the active molecules present in vector saliva. Immediate, delayed and systemic hypersensitivity reactions to vector saliva have been described reviewed in Andrade et al. (2005). Vertebrate responses to arthropod salivary components have been used as epidemiological markers for vector exposure for ticks (Schwartz et al. 1991), phlebotomines (Barral et al. 2000, Gomes et al. 2002), *Triatoma* (Nascimento et al. 2001), *Glossina* (Poisignon et al. 2008b) and *Aedes* mosquitoes (Remoue et al. 2007). In the case of malaria, the host immune response against vector saliva can be used as a biomarker of exposure to *Anopheles*.

**Biomarkers of susceptibility**. There is now strong evidence that high frequencies of genetic disorders, predominantly those involving haemoglobin and red blood cell metabolic pathways and membranes, reflect relative resistance to malaria. One of the most famous genetic disorders associated with protection against death or severe disease is the sickle cell trait, haemoglobin S (Hbs).

---

**Fig. 3: key insights in biomarkers.** Biomarker is anything that can be used as an indicator of a particular disease state or other physiological state. Indeed, biomarkers can be used to discriminate pathological from non-pathological conditions during diagnosis (A). Certain biomarkers are more useful for diagnosis (e.g. fever to infer Plasmodium infection), whereas others are used to predict the disease severity (e.g. coma or severe anaemia). A relevant biomarker must present very high sensitivity (few false negatives) and specificity (few false positives) to the prediction of a certain clinical endpoint (B). A surrogate marker is a laboratory measurement or a physical sign used as a substitute for a clinically meaningful endpoint that measures directly how a patient feels, functions or survives. Changes induced by a therapy on a surrogate marker are expected to reflect changes in a clinically meaningful endpoint. Thus, the primary difference between a biomarker and a surrogate marker is that a biomarker is a “candidate” surrogate marker, whereas a surrogate marker is a validated test used and taken as a measure of the effects of a specific treatment (Katz 2004).
The gene for HbS is widely distributed throughout many tropical regions, including sub-Saharan Africa, the Middle East and India. The first study to propose the relationship between the HbS variant and *P. falciparum* malaria showed high frequencies of the sickle cell trait in non-infected children from highly endemic areas and a relative rarity of HbS in individuals with severe disease [reviewed in Weatherall (2008)]. Although the mechanism of protection remains unknown, it has been established that the parasitised erythrocytes from a patient with sickle cell trait are much more susceptible to sickling compared to non-parasitised cells (Luzzatto et al. 1970). Thus, the removal of sickling red cells in the spleen increases the rate of parasite clearance, reducing parasitaemia and therefore the magnitude of symptoms. In addition, sickle cell carriers had significantly higher titres of IgG antibodies against a panel of malaria antigens compared to non-carrier children (Cabrera et al. 2005). A range of other possible mechanisms, however, may protect sickle cell trait carriers from severe malaria and these should be explored in further studies.

Many other red blood cell mutations, such as haemoglobin C (Fairhurst et al. 2005) and alpha thalassaemia (Allen et al. 1997, Mockenhaupt et al. 2004, Williams et al. 2005) are associated with some degree of protection against *P. falciparum* malaria. The mechanisms of protection against malaria are commonly linked to reduced parasite replication within infected cells or the enhanced clearance of infected erythrocytes resulting from abnormal erythrocyte fragility (Pasvol et al. 1978, 1982, López et al. 2010). For other genetic disorders, the mechanism of protection is less well understood; this is the case for glucose-6-phosphate-dehydrogenase (G6PD) deficiency, the most common enzymopathy worldwide (Nkhoma et al. 2009). It is likely that this condition enhances red blood cell fragility as a result of increased susceptibility to oxidative stress (Cappadoro et al. 1998). Although it is protective against malaria, G6PD deficiency is also linked to a severe haemolytic syndrome triggered by primaquine, a primary drug used to treat *P. vivax* infections (Cappadoro et al. 1998). Beyond advancing the understanding of protective mechanisms, more effort is needed in applying this knowledge to the development of practical prophylactic or therapeutic tools.

The Duffy blood group antigen illustrates how genetic epidemiology can drive essential insights into the molecular basis of malaria. Epidemiological studies first suggested that individuals lacking the Duffy antigen/chemokine receptor (DARC) were relatively protected against *P. vivax* malaria (Miller et al. 1976). Later evidence revealed that *P. vivax* molecules bind to DARC and are important for parasite invasion (Chitnis & Miller 1994). Recent studies have shown that *P. vivax* infections are common in Duffy-negative people (Cavasini et al. 2007a, b, Ménard et al. 2010), bringing attention to the question of the real role of Duffy antigens in *Plasmodium* infectivity.

In addition to genetic determinants, there are a number of other interesting markers of malaria susceptibility. One such marker is the initial inflammatory response to *Anopheles* bites. Levels of antibodies against *An. gambiae* saliva were higher in young children who developed clinical malaria episodes than those that remained asymptomatic; these findings were interpreted to mean that the anti-saliva response is a potential marker for the risk of *P. falciparum* malaria (Remoue et al. 2006). Additionally, individuals with asymptomatic *P. vivax* parasitaemia presented higher anti-saliva antibody titres and a lower interferon-gamma (IFNγ)/interleukin (IL)-10 ratio than symptomatic individuals; furthermore, the IFNγ/IL-10 ratio was inversely correlated to anti-SGS titres in asymptomatic individuals (Andrade et al. 2009). Unfortunately, there is little data regarding cellular immune responses against salivary antigens; such responses are commonly observed in other diseases such as leishmaniasis (Gomes et al. 2002). It is important to verify whether the manipulation of a host’s immune response against vector saliva can influence susceptibility to infection.

It is well established that antibodies and T cells have crucial roles in protective immunity against the different life cycle stages of *Plasmodium* (Good et al. 1998). Antibodies against merozoite surface molecules inhibit parasite invasion of new erythrocytes (Gilha et al. 2000). Some classes of antibodies, mainly the IgG isotype, directed against antigens of *P. falciparum* erythrocytes are important in antimalarial immunity; the transfer of serum from an immune person to a non-immune is protective against infection (McGregor 1964). Humoral responses can also target sporozoites, reducing parasite invasion of hepatocytes (Hisaeda et al. 2005) or, as the case of anti-*P. falciparum* merozoite surface protein 1, humoral responses can interfere with the attachment of infected erythrocytes to the endothelium (Gilha et al. 2000). Furthermore, specific antibodies against glycosylphosphatidylinositol, an immunostimulatory molecule, suppress macrophage activation, thus decreasing cytokine production and inflammation (Schofield et al. 2002). Additionally, host antibodies directed against gametocytes interfere with the transmission of parasites to new vector mosquitoes. Although this type of immunity does not protect infected individuals, it may help to reduce infection at the community level.

**Biomarkers of severity** - Severe malaria is a highly lethal condition that requires intensive care. As a result of their immunocompromised state, children and pregnant women are the most susceptible to complications from *P. falciparum* infection. Although severe cases of *vivax* malaria are also associated with younger age (Andrade et al. 2010c), adults appear to be susceptible even in regions with moderate to high endemicities. Multiple factors have been implicated in the pathogenesis of severe malaria caused by either *P. vivax* or *P. falciparum* infection, including uncontrolled cytokine production (Clark et al. 2006), intense haemolysis (Yeo et al. 2009, Andrade et al. 2010a) and erythropoiesis suppression (Lamikanra et al. 2007). In addition, systemic endothelial damage and obstruction of blood flow are important contributors to lethal outcomes, mainly in *P. falciparum* infections (Schofield & Grau 2005, Schofield 2007).

Several different biomarkers have been described as useful predictors of severe malaria and many of these were discovered based on understanding of *Plasmodium*...
immunopathogenesis. The majority of what is known concerning severe malaria is related to *P. falciparum* infections, most likely because of this parasite’s huge disease burden in Africa. Because *P. vivax* infection has been relatively neglected compared to *falciparum* malaria, the factors involved in its pathogenesis are less well understood; furthermore, biomarkers for *vivax* malaria susceptibility and disease severity are largely unknown. Many factors have been associated with severe forms of malaria and most efforts have focused on distinguishing cerebral malaria (CM) and severe malarial anaemia from other diseases caused by uncomplicated infections. One simple factor that can influence malaria severity is parasitaemia. In *P. falciparum* infections, parasitaemia is directly linked to the severity of symptoms (WHO 2000). In *vivax* malaria, the limit of parasitaemia that can trigger pathological events is lower, so patients with relatively few circulating parasites can exhibit the inflammatory cytokine overproduction that results in fever and other complications (Karunaweera et al. 1992, Hemmer et al. 2006). In addition, as *P. vivax* preferentially infects reticulocytes, parasitaemia rarely exceeds 2% of circulating red blood cells and high parasite burdens are not a common feature of severe *vivax* malaria. Indeed, in two studies carried out in the Brazilian Amazon, patients with severe *vivax* malaria presented diverse parasite burdens (Alexandre et al. 2010, Andrade et al. 2010c). Differentiating CM from other causes of serious illness in endemic areas is complicated by the non-specific clinical presentation and the high prevalence of incidental *P. falciparum* parasitaemia (Conroy et al. 2010). Knowledge of the pathogenesis of CM and the identification of cytadherence in *P. falciparum* and *P. vivax* (Carvalho et al. 2010) led us to test mediators associated with endothelial activation or damage. The angiogenic factor angiopoietin-2 is released from endothelial cells with reduced nitric oxide bioavailability in cases of CM (Lovegrove et al. 2009); it contributes to endothelial activation, sequestration of parasite biomass, impaired perfusion and poor clinical outcome (Yeo et al. 2008). Other strong predictors of CM that can be measured in plasma are intracellular adhesion molecule-1 (Conroy et al. 2010), interferon gamma-inducible protein 10 (IP-10), soluble tumour necrosis factor receptors (sTNF-R) and soluble FAS molecules. These molecules were independently associated with increased risk of CM-associated mortality (Jain et al. 2008). Many other markers, including IFNγ, IP-10, IL-8, MIP-1β, IL-1RA, FAS-L, sTNF-R1 and sTNF-R2, could be identified in the cerebrospinal fluid of patients with lethal CM, suggesting their involvement in CM neuropathology (Yeo et al. 2008). Recently, cell-specific microparticles, which indicate cellular damage, were demonstrated to be biological markers for cerebral dysfunction in human CM (Pankoui Mfonkeu et al. 2010). Interestingly, elevated plasma concentrations of microparticles were also found in individuals with non-complicated *P. vivax* infection in a study conducted in the Brazilian Amazon (Campos et al. 2010), suggesting that platelet-derived microparticles may play a role in the onset of acute inflammatory symptoms of *vivax* malaria. These results also suggest that the microparticles are a potential biomarker for severity of malaria caused by *P. falciparum* or *P. vivax*. Many of these candidate biomarkers could be combined in a multiplex immunoassay, which could be validated in broader applications.

IL-10, together with TNF-α and erythropoietin, has been described as a good predictor of severe anaemia (Ageley et al. 2008, Ouma et al. 2008). Recently, the IFNγ/IL-10 ratio has been successfully used as a marker for pathological inflammatory activity in patients with varying disease severity (Andrade et al. 2010c). The most famous inflammatory marker of severe malaria is TNF-α, which is tightly associated with fever, paroxysms, anaemia, CM (Karunaweera et al. 2003, Armah et al. 2005) and many other systemic symptoms of the infection.

It is worthy of note that as all of these markers are based on immunopathogenesis and not on the presence of the parasite itself, they have limitations in their use. After differential diagnosis, but before the onset of severe symptoms, some biomarkers can be used as predictors of complications or mortality, which could prove important in the management of potentially lethal infections. Accordingly, factors that indicate not only inflammatory status but also oxidative stress and damage to specific organs can easily be used in predictive models; they may serve as surrogate markers of disease severity. In addition, as the objective of the prediction is to influence the clinical outcome, the specificity of these markers is not critical. Indeed, non-parasite-specific markers have been shown to be powerful tools. Haemolysis, for example, is inherent to the *Plasmodium* life cycle during the symptomatic phase of the disease (Ekvall et al. 2001). The acute haemolysis observed in severe malaria cases results in abnormally high concentrations of free heme, which subsequently induces the production of superoxide radicals (Delmas-Beauvieux et al. 1995), cell death (Gozzelino & Soares 2011) and an imbalance between pro-inflammatory and anti-inflammatory mediators (Andrade et al. 2010a). Recently, we have shown that haemolysis related to high plasma levels of indirect bilirubin, total heme and Cu/Zn superoxide dismutase (SOD1) is consistently associated with severe *vivax* malaria (Andrade et al. 2010a). Furthermore, SOD1 is a better predictor of severe *vivax* malaria than are plasma levels of TNF-α (Andrade et al. 2010d), but this biomarker cannot be used to discriminate between *P. vivax* and *P. falciparum* infections. In a recent study of a cohort of patients with different clinical presentations of *vivax* malaria, we described a series of promising markers of severe disease (Andrade et al. 2010c). These markers can be easily measured and can be used to generate a score that is strongly associated with unfavourable outcomes. The markers included plasma creatinine, urea, C reactive protein, fibrinogen, bilirubins, hepatic transaminases and heme oxygenase-1. Some of these mediators were evaluated and found to have very high discriminating power (Fig. 4). A summary of some promising biomarkers of clinical protection or disease severity is illustrated in Fig. 5.

**Future perspectives** - Although much published data exists regarding new biomarkers for malaria susceptibility and disease severity, few studies provide validation of their results using large samples or multi-centre ap-
Infections in native Amazonian and Brazilian Amazon during 2006–2007. Aside from 2006–2007. Information about this cohort of patients can be found elsewhere (Andrade et al. 2010c). Receiver operator characteristics curves were used to compare the power of each mediator to discriminate severe malaria cases from mild infections. The area under the curve is a primary way to compare the power of each marker. Within these candidate markers, sTNF-R I presented the highest sensitivity, specificity, and likelihood ratio to predict severe cases of malaria. Larger prospective studies are necessary to validate these findings.

**ACKNOWLEDGEMENTS**

To Dr Daniel L Barber, for critical discussions.

**REFERENCES**


